Study Findings from Huzhou Central Hospital Provide New Insights into Colon Cancer [Immunotherapy combined with local therapy in the late-line treatment of repair-proficient (pMMR)/microsatellite stable (MSS) metastatic colorectal cancer].

A study conducted at Huzhou Central Hospital in China explores the use of immunotherapy combined with local therapy in the treatment of metastatic colorectal cancer (mCRC) that is repair-proficient (pMMR)/microsatellite stable (MSS). The researchers note that while immunotherapy is effective for a small proportion of patients with mCRC, the majority of patients with pMMR/MSS mCRC do not benefit from it. The study examines the potential of combining immunotherapy with local therapies such as radiotherapy, ablation, and transcatheter arterial chemoembolization to address this issue. The research provides insights into current studies and possible mechanisms for this combined treatment approach. [Extracted from the article]

Copyright of Immunotherapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)